Idera Pharmaceuticals Announces Jonathan Wilkin, M.D., to Join Autoimmune Disease Scientific Advisory Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals (Nasdaq: IDRA), a biopharmaceutical company developing therapeutics targeting Toll-like Receptors (TLRs) and advancing gene-silencing oligonucleotide (GSO) technology, today announced that Jonathan Wilkin, M.D., has joined its Autoimmune Disease Scientific Advisory Board.

“Dr. Wilkin brings to Idera extensive regulatory affairs experience, having served as a Director at the FDA for more than 10 years,” said Sudhir Agrawal, D. Phil., Chairman and Chief Executive Officer. “We welcome Dr. Wilkin as our advisor, and look forward to his contributions as we prepare to advance our lead TLR7/TLR9 antagonist compound, IMO-3100, into to clinical proof-of-concept studies in selected autoimmune disease indications.”

Jonathan K. Wilkin, M.D., was the founding director of the Division of Dermatology and Dental Products at the US Food and Drug Administration and has previously been a member of the FDA’s Dermatology Drugs Advisory Committee. Dr. Wilkin is a fellow of the American Academy of Dermatology and the American College of Physicians, a member of the American Dermatological Association, and board certified by both the American Board of Dermatology and the American Board of Clinical Pharmacology. Previously, Dr. Wilkin served as the Director of Dermatology at the Ohio State University and Professor of Pharmacology and Medicine. Dr. Wilkin received his BA and MS in zoology from Ohio State University in Columbus, followed by his medical degree from the Ohio State University College of Medicine.

About Idera

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Additionally, the company is advancing gene-silencing oligonucleotide (GSO) technology for the purpose of inhibiting the expression of disease-promoting genes. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.



CONTACT:

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
[email protected]
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.